ClinicalTrials.gg
RecruitingNCT05475574Ger-SPUpdated Jun 24, 2026

Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit

An interventional study of Discontinuation of contact precautions for ESBLE in Infection, Hospital, sponsored by Centre Hospitalier Régional Metz-Thionville. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
954
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study.

The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.

Read the detailed description

Healthcare-associated infections (HAIs) are one of the main causes of morbidity and mortality worldwide. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have become microorganisms frequently found in HAIs, which reduces the therapeutic possibilities.

02

Conditions studied

  • Infection, Hospital

Browse trials for

03

In context

Cross Infection

285 studies on the registry are indexed under Cross Infection; 48 are open to participants now.

This study's planned enrollment of 954 is above the median of 185 across 169 interventional studies indexed under Cross Infection.

Browse Cross Infection studies →

Lead sponsor

Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 123 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (> 65 years old)
  • Patient hospitalized in geriatrics during the study period
  • Free and obtained from the patient (or his trusted person or legal representative) within 48 hours of its admission at the geriatric unit
  • Patient affiliated to a social security scheme

Non Inclusion Criteria:

  • Patient requiring contact precaution for an indication other than ESBLE (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC) on admission
  • Patient under legal protection
  • Person deprived of liberty

Exclusion criteria

Exclusion criteria:

  • Patient requiring contact precaution for an indication other than ESBL during the patient stay (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC)
  • Patient's stay period less than 4 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
954 participants (estimated)

Study arms

  • No intervention
    Before discontinuation of contact precautions for ESBLE

    Implementation of contact precaution in addition to standard precaution for any patient carrying (infected or colonized) ESBLE

  • Experimental
    After discontinuation of contact precautions for ESBLE

    Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE

    Other: Discontinuation of contact precautions for ESBLE

Interventions

  • OtherDiscontinuation of contact precautions for ESBLE

    Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE

06

What researchers measure

Primary outcomes

  1. Incidence density of acquired ESBLE

    Incidence density of acquired ESBLE in geriatric unit for 1000 days of hospitalization is calculated by dividing the number of acquired ESBLE by the number of days of patients' hospitalization multiplied by 1000 Acquisition of ESBLE is defined by a positive sample in patient on discharge day with a negative sample on admission in geriatric unit A positive sample is defined by the presence of at least one ESBLE on a clinical (infection) or screening (colonization) sample. The hospitalisation number is calculated as the cumulative length of stay of all patients at risk (= negative on admission).

    Time frame: during 6 month period

Secondary outcomes

  1. Incidence density of acquired ESBLE by species during 6 month period

    Incidence density of acquired ESBLE in geriatric unit by species (E. coli versus non-E. coli) for 1000 days of hospitalization. This is calculated by dividing the number of acquired ESBLE by species by the number of days of patients' hospitalization multiplied by 1000. Acquisition of ESBLE is defined by a positive sample in patient on discharge day with a negative sample on admission in geriatric unit A positive sample is defined by the presence of at least one ESBLE on a clinical (infection) or screening (colonization) sample. The hospitalisation number is calculated as the cumulative length of stay of all patients at risk (= negative on admission).

    Time frame: during 6 month period

  2. The rate of compliance with hand hygiene in health care providers

    The evaluation of the compliance with hygiene measures is calculated in health care providers by dividing the number of hand hygiene moments carried out by the number of opportunities multiplied by 100, according to the World Health Organization (WHO) methodology

    Time frame: Up to 3 months per health department

  3. Evaluation of the barriers to alcohol-based hand rub in case of non-compliance in health care providers

    The barriers to alcohol-based hand rub are identified in case of non-compliance, using a Pulpe' friction questionnaire (RéPIAS) where professionals are interviewed about their practices in terms of hand hygiene. For each situation, the professional is also asked how important it is for him to perform hand hygiene in each situation listed above, with a slider to be positioned between 0 (not at all important; worse outcome) and 10 (the most important; better outcome).

    Time frame: Up to 3 months per health department

  4. The rate of compliance with personal protective equipment

    The rate of compliance with the wearing and removal of personal protective equipment throughout patient care, is observed during care related to the management of excreta (changing, putting on or removing a dish basin, use of a basin washer-disinfector). The rate is calculated by dividing the number of personal protective equipment good caring practices by the number of opportunities multiplied by 100.

    Time frame: Up to 3 months per health department

  5. Evaluation of satisfaction related to patient care, by self-questionnaire Hospital anxiety and depression scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item measure designed to assess anxiety and depression symptoms in medical patients, with emphasis on reducing the impact of physical illness on the total score. Items are rated on a 4-point severity scale. The HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states. Scores of greater than or equal to 11 on either scale indicate a definitive case.

    Time frame: on the day of discharge of the geriatric unit, on average on the 11th day

07

Study locations

1 of 1 sites recruiting
  • CHR Metz-Thionville/Hôpital Bel Air
    Metz, 57085, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05475574
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
Mar 7, 2023
Primary completion
Sep 7, 2029 (estimated)
Completion
Sep 21, 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Laurie RENAUDIN, MD
Contact
l.renaudin@chr-metz-thionville.fr
03 87 55 30 25 ext. 0033
Mathieu LLORENS, MD
Contact
m.llorens@chr-metz-thionville.fr
03 87 55 38 39 ext. 0033
Noel BLETTNER, MD
principal investigator · Mercy Hospital CHR Metz Thionville
Azzeddine AZZEMOU, MD
principal investigator · Bel Air Hospital CHR Metz Thionville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion